SCHEMBL22659076

SCHEMBL22659076

Cc1cccc(-c2cnc3cc(C(=O)Nc4cc(C(F)(F)F)nn4C)ccc3c2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ WDR5 P61964 1/20 0.45
▸ NTRK1 P04629 2/20 0.44
▸ KCNT1 Q5JUK3 3/20 0.43
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ MAPK14 Q16539 1/20 0.40
▸ BRAF P15056 2/20 0.39
▸ STIM1 Q13586 1/20 0.39
▸ ORAI1 Q96D31 1/20 0.39
▸ GRM5 P41594 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ TRPM8 Q7Z2W7 1/20 0.39
▸ MMP9 P14780 1/20 0.39
▸ GRIN2B Q13224 2/20 0.39
▸ KCNK3 O14649 1/20 0.39
▸ KCNK9 Q9NPC2 1/20 0.39
▸ GRIN1 Q05586 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22659317 0.92 KCNT1 (0.47) WDR5NTRK1KCNT1MAPTMAPK14
SCHEMBL22659822 0.91 LCK (0.45) BRAFGRIN2BGRIN1
SCHEMBL24571213 0.91 NTRK1 (0.47) NTRK1MAPTMAPK14BRAFSTIM1
SCHEMBL29406420 0.91 NTRK1 (0.47) NTRK1MAPTMAPK14BRAFSTIM1
SCHEMBL22659814 0.90 STIM1 (0.44) NTRK1KCNT1STIM1ORAI1GRM5
SCHEMBL22659336 0.90 HTR2C (0.44) WDR5NTRK1BRAFSTIM1ORAI1
SCHEMBL29403796 0.87 KCNT1 (0.48) WDR5NTRK1KCNT1MAPK14BRAF
SCHEMBL22659854 0.87 KCNT1 (0.48) WDR5NTRK1KCNT1MAPK14BRAF
SCHEMBL22659319 0.87 HPGDS (0.42) NTRK1KCNT1BRAFSTIM1ORAI1
SCHEMBL29405919 0.87 HPGDS (0.42) NTRK1KCNT1BRAFSTIM1ORAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312337-B2 Compounds and methods for treating cancer ANTIDOTE IP HOLDINGS, LLC (US) 2025-05-27 — — US disclosed
US-20220204482-A1 COMPOUNDS AND METHODS FOR TREATING CANCER ANTIDOTE IP HOLDINGS, LLC 2022-06-30 — — US disclosed
US-20220204482-A1 COMPOUNDS AND METHODS FOR TREATING CANCER ANTIDOTE IP HOLDINGS, LLC 2022-06-30 — — US disclosed
EP-3966208-A2 COMPOUNDS AND METHODS FOR TREATING CANCER Antidote IP Holdings, LLC (US) 2022-03-16 — — EP disclosed
WO-2020231739-A2 COMPOUNDS AND METHODS FOR TREATING CANCER ANTIDOTE IP HOLDINGS, LLC (US) 2020-11-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204482-A1 COMPOUNDS AND METHODS FOR TREATING CANCER AHR, ARNT, HMOX1 WDR5 1966/4885NTRK1 2504/4885KCNT1 3974/4885
US-12312337-B2 Compounds and methods for treating cancer AHR, ARNT, HMOX1 WDR5 1966/4885NTRK1 2504/4885KCNT1 3974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback